CDH and TOF are distinct disorders, but both can place severe demands on the developing body. In CDH, an abnormal opening in the diaphragm allows abdominal organs to move into the chest, restricting lung development and often producing pulmonary hypoplasia and pulmonary hypertension. TOF is a heart defect involving four anatomical abnormalities, including a ventricular septal defect, obstruction of blood flow from the right ventricle to the lungs, an overriding aorta and thickening of the right ventricular muscle. The clinical severity of both disorders can vary widely, making early risk assessment difficult. Physicians currently rely on imaging, physiological measurements, blood tests and clinical observation, but these approaches do not always reveal the molecular processes unfolding inside the patient.

Proteomics focuses on the complete collection of proteins present in a biological sample. Unlike genes, which provide a relatively stable blueprint, proteins change in response to development, inflammation, oxygen deprivation, tissue injury, infection and medical treatment. Urinary proteomics applies advanced analytical techniques—often liquid chromatography coupled with tandem mass spectrometry—to identify and quantify hundreds or thousands of proteins and protein fragments. Because urine contains molecules filtered from the blood as well as substances released by the kidneys and urinary tract, its protein profile can reflect systemic changes while avoiding the invasiveness of tissue sampling.

For newborns and critically ill children, that advantage could be especially important. Repeated blood draws can contribute to anemia and may be technically challenging, while tissue biopsies are rarely practical for monitoring congenital disease. Urine collection can be performed using diapers, collection bags or other pediatric sampling methods, potentially allowing researchers to track molecular changes over time. A single sample might contain information about inflammation, vascular development, extracellular-matrix remodeling, kidney stress, cardiac workload or the effects of intensive-care treatment. The goal is not simply to find one “disease protein,” but to identify reproducible patterns that distinguish biological states and predict how a child may progress.

In CDH, urinary protein signatures could help clarify why some infants develop severe respiratory failure while others respond more favorably to treatment. The degree of lung underdevelopment is not always easy to estimate before birth or immediately after delivery, and pulmonary hypertension can evolve rapidly. Proteomic patterns associated with abnormal blood-vessel formation, inflammatory signaling or impaired tissue maturation might provide additional clues about disease severity. Such information could eventually complement prenatal imaging, oxygenation measurements and postnatal imaging when clinicians are deciding how aggressively to support breathing, circulation and pulmonary blood flow.

The same strategy could be valuable in TOF, where anatomical differences do not always fully predict a child’s clinical course. Infants may experience altered oxygen delivery, right-ventricular pressure overload and changes in kidney perfusion before or after surgical repair. Urinary proteins linked to myocardial stress, vascular signaling, fibrosis or organ injury could help researchers study how the heart and other organs respond to these pressures. After surgery, serial urine samples might also reveal biological recovery or emerging complications earlier than conventional measurements. However, the article’s focus is on potential: urinary proteomics remains a developing research approach rather than a validated bedside test for routine diagnosis.

Turning promising protein patterns into reliable clinical tools will require rigorous validation. Urine is highly variable, and its composition can be influenced by hydration, feeding, gestational age, medication, infection, kidney function and the timing of collection. In premature or critically ill infants, these factors may change dramatically within hours. Researchers must therefore standardize collection and storage procedures, normalize protein measurements—often by accounting for urine concentration—and include sufficiently large patient groups. Results discovered in one hospital may not perform identically in another if instruments, laboratory protocols or patient populations differ.

Another challenge is separating signals caused by the congenital condition from signals produced by treatment. Mechanical ventilation, antibiotics, diuretics, surgery, transfusions and extracorporeal support can all alter the urinary proteome. A protein pattern observed after an operation might reflect tissue recovery, inflammation from surgery or medication exposure rather than the original heart or lung defect. Longitudinal studies that collect samples before treatment, during critical illness and throughout recovery will be essential. Researchers will also need to compare affected infants with carefully selected control groups, including healthy newborns and children undergoing treatment for unrelated conditions.

The technical power of proteomics is expanding rapidly. Modern mass spectrometers can detect low-abundance proteins with increasing sensitivity, while computational tools can identify networks of interacting molecules rather than examining each protein in isolation. Machine-learning models may eventually combine urinary protein profiles with echocardiography, imaging, genomic data and bedside measurements to produce individualized risk estimates. Yet sophisticated prediction is only useful if it is transparent, reproducible and clinically meaningful. A biomarker must ultimately improve a decision—such as determining monitoring intensity, timing an intervention or identifying complications early—rather than merely generating an impressive molecular signature.

“Testing the waters” highlights why urine is attracting attention as a source of pediatric biomarkers: it is accessible, repeatable and rich in biological information. For CDH and TOF, two disorders in which early development, cardiopulmonary physiology and treatment response are tightly intertwined, this approach could open a new path toward precision medicine. The next step is not to promise an immediate diagnostic revolution, but to build carefully designed studies that test whether urinary proteins consistently reflect disease severity and predict outcomes. If those findings hold up across hospitals and diverse patient populations, a sample that is usually discarded could become a powerful tool for watching vulnerable children heal.

Subject of Research: Urinary proteomics as a potential tool for studying, monitoring and predicting outcomes in congenital diaphragmatic hernia and Tetralogy of Fallot.

Article Title: Testing the waters: the potential of urinary proteomics in congenital diaphragmatic hernia and Tetralogy of Fallot.

Article References: Stiffler, E.A., Alcocer, A.D. & Mead, T.J. “Testing the waters: the potential of urinary proteomics in congenital diaphragmatic hernia and Tetralogy of Fallot.” Pediatric Research (2026). https://doi.org/10.1038/s41390-026-05387-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-026-05387-5

Keywords: urinary proteomics, congenital diaphragmatic hernia, Tetralogy of Fallot, pediatric biomarkers, congenital heart disease, pulmonary hypoplasia, precision medicine

Congenital diaphragmatic hernia is a severe developmental anomaly characterized by the improper formation of the diaphragm, allowing abdominal organs to herniate into the thoracic cavity. This displacement severely impairs lung development and function, often leading to pulmonary hypoplasia and chronic respiratory distress after birth. Despite advances in neonatal care, CDH remains a leading cause of neonatal morbidity and mortality worldwide. The precise evaluation of fetal lung maturity and vascularization is crucial for tailoring perinatal interventions and improving clinical outcomes. However, current prenatal imaging modalities, primarily ultrasound, have inherent limitations in sensitivity and quantitative assessment.

Ultrasound, the clinical standard for fetal lung evaluation, suffers from operator dependency and limited resolution, especially in complex cases complicated by CDH. It provides mostly qualitative or semi-quantitative data, insufficient for confidently predicting respiratory function postnatally. In contrast, magnetic resonance imaging (MRI) offers superior soft tissue contrast and higher spatial resolution, enabling detailed visualization of lung morphology. Within MRI modalities, T2 relaxation time—reflecting tissue oxygenation and microstructural properties—has emerged as a promising biomarker. The T2 value corresponds to the decay of transverse magnetization affected by local magnetic field inhomogeneities, which are in turn influenced by levels of blood oxygenation and iron presence.

The recent study conducted by Forth and Tingay delves into the application of pulmonary T2 quantification in fetuses diagnosed with CDH, seeking to establish correlations between T2 measurements and lung health. Using advanced MRI sequences optimized for fetal imaging, the researchers measured T2 values in the lungs during the critical developmental window. The methodology involves capturing multi-echo gradient echo images to calculate T2 decay curves with precision. This quantitative technique allows assessing not only lung volume but also functional parameters such as oxygenation status, which are vital for understanding pulmonary hypoplasia severity.

One of the fundamental strengths of pulmonary T2 quantification lies in its non-invasive nature and ability to deliver objective data beyond conventional imaging. Unlike Doppler ultrasound, which assesses blood flow indirectly, T2 MRI offers direct insights into tissue oxygenation by exploiting magnetic susceptibility effects. This represents a paradigm shift in prenatal evaluation, as it facilitates early detection of compromised lung function before structural deficits become overt. Early identification can guide critical clinical decisions, including the timing of delivery, administration of steroids to enhance lung maturation, or planning of fetal surgical interventions.

Technically, the integration of fetal motion compensation algorithms and rapid acquisition sequences has overcome previous barriers to implementing T2 imaging in utero. Fetal MRI is inherently challenging due to constant movement and limited acquisition windows. However, innovations such as prospective motion correction, real-time image registration, and single-shot echo planar imaging have enabled reliable collection of T2 data. These advancements ensure that pulmonary T2* quantification is feasible, reproducible, and clinically applicable for a broad spectrum of cases, including those with severe diaphragmatic defects.

Furthermore, the study’s data reveal significant differences in T2 values between CDH-affected lungs and healthy controls, highlighting the potential of T2 to serve as a biomarker distinguishing varying degrees of pulmonary hypoplasia. Lower T2* values are indicative of reduced oxygenation and altered vascular density, correlating with worse respiratory outcomes postnatally. This quantitative imaging biomarker could thus inform risk stratification models, enabling clinicians to identify fetuses at highest risk who might benefit most from intensive monitoring and specialized therapies after birth.

From a pathophysiological perspective, T2 quantification offers an unprecedented window into the microenvironment of the developing lung. Changes in T2 reflect alterations in alveolar-capillary network formation, hemoglobin oxygen saturation, and tissue iron metabolism, all crucial for healthy pulmonary maturation. Understanding these parameters in vivo helps elucidate the mechanisms underlying CDH-related lung impairment, potentially revealing novel therapeutic targets. For example, if T2* mapping identifies regions of impaired oxygen delivery or vascular growth, targeted interventions to promote angiogenesis might be explored safely in utero.

The translation of T2 MRI quantification into routine clinical workflows could transform prenatal counseling as well. Currently, prognostic discussions often rely on empirical measures and qualitative findings. Quantitative T2 measurements provide objective data to better predict neonatal respiratory capacity, thereby reducing uncertainty for families and care teams. Enhanced prognostication would also optimize resource allocation, enabling neonatal intensive care units to prepare appropriately and anticipate complications with greater confidence.

Beyond CDH, the implications of pulmonary T2 imaging extend to a spectrum of fetal lung disorders, including pulmonary hypoplasia due to oligohydramnios, cystic malformations, or congenital infections. The ability to noninvasively measure tissue oxygenation and structure in the developing lung introduces a new dimension to fetal medicine. Future research may explore longitudinal T2 monitoring to track lung maturation trajectories over gestation, potentially assessing response to in utero therapies such as tracheal occlusion or pharmacological agents.

While promising, implementing pulmonary T2 quantification in clinical practice requires overcoming several hurdles. Standardization of MRI protocols across centers, validation of normative T2 values at different gestational ages, and integration with existing diagnostic algorithms are necessary. Large multicenter studies will be essential to confirm the robustness of T2* as a predictive biomarker and to define thresholds that correlate with functional outcomes. Moreover, cost-effectiveness analyses must be conducted to justify widespread adoption in high-risk pregnancies.

Ethical considerations also arise, as enhanced imaging capability might lead to more complex decision-making regarding fetal interventions and delivery planning. Multidisciplinary collaborations among radiologists, neonatologists, obstetricians, and ethicists will be crucial to ensure that cutting-edge fetal imaging techniques are deployed responsibly and equitably, maximizing benefits while minimizing potential harm.

In conclusion, the quantification of pulmonary T2 presents a revolutionary approach to fetal lung assessment in congenital diaphragmatic hernia, moving beyond the constraints of ultrasound to embrace a quantitative, functional imaging paradigm. By accurately characterizing lung oxygenation and microstructure in utero, this technique promises to improve diagnosis, guide therapeutic strategies, and ultimately enhance neonatal outcomes. As fetal MRI technology continues to evolve, pulmonary T2 quantification stands at the forefront of personalized prenatal medicine, illuminating the path toward safer and more effective management of complex congenital lung diseases.

Subject of Research: Pulmonary T2* quantification as a diagnostic tool for fetal lung status assessment in congenital diaphragmatic hernia.

Article Title: Pulmonary T2* quantification of fetal lung status in congenital diaphragmatic hernia: future alternative to ultrasound?

Article References:
Forth, A., Tingay, D.G. Pulmonary T2 quantification of fetal lung status in congenital diaphragmatic hernia: future alternative to ultrasound?. Pediatr Res* (2025). https://doi.org/10.1038/s41390-025-04241-4

Image Credits: AI Generated